Financial Results:Through the third quarter of fiscal 2013, we generated product revenue from the sale of Dermacyte® through on-line retailers, physicians and medical spa facilities, and through distribution agreements with unrelated companies. Net product revenue for the years ended April 30, 2013 and 2012 was $49,572 and $49,266, respectively. The decrease in product revenue was primarily due to the elimination of our internal sales force and the suspension of our direct marketing and advertising programs. Gross profit as a percentage of revenue was 53% and 49% for the years ended April 30, 2013 and 2012, respectively. In the fourth quarter of fiscal 2013 we out-licensed the Dermacyte® product line to the cosmetics division of Valor SA of Switzerland.
Oxygen Biotherapeutics Reports Financial Results For Fiscal Year 2013
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.